CN115068634A - Application of tumor targeting polypeptide - Google Patents
Application of tumor targeting polypeptide Download PDFInfo
- Publication number
- CN115068634A CN115068634A CN202210359401.0A CN202210359401A CN115068634A CN 115068634 A CN115068634 A CN 115068634A CN 202210359401 A CN202210359401 A CN 202210359401A CN 115068634 A CN115068634 A CN 115068634A
- Authority
- CN
- China
- Prior art keywords
- tumor
- imaging
- yqga
- hynic
- spect
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 220
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 63
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 61
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 61
- 230000008685 targeting Effects 0.000 title claims abstract description 27
- 238000003384 imaging method Methods 0.000 claims abstract description 27
- 239000007850 fluorescent dye Substances 0.000 claims abstract description 20
- 238000003745 diagnosis Methods 0.000 claims abstract description 16
- 238000012634 optical imaging Methods 0.000 claims abstract description 8
- 239000000523 sample Substances 0.000 claims description 79
- 150000001875 compounds Chemical class 0.000 claims description 70
- 238000002360 preparation method Methods 0.000 claims description 38
- 239000012216 imaging agent Substances 0.000 claims description 12
- 239000003153 chemical reaction reagent Substances 0.000 claims description 11
- 238000000799 fluorescence microscopy Methods 0.000 claims description 11
- 230000001588 bifunctional effect Effects 0.000 claims description 8
- 239000002738 chelating agent Substances 0.000 claims description 8
- 230000004807 localization Effects 0.000 claims description 5
- 239000000539 dimer Substances 0.000 claims description 4
- JHALWMSZGCVVEM-UHFFFAOYSA-N 2-[4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl]acetic acid Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CC1 JHALWMSZGCVVEM-UHFFFAOYSA-N 0.000 claims description 2
- RXACEEPNTRHYBQ-UHFFFAOYSA-N 2-[[2-[[2-[(2-sulfanylacetyl)amino]acetyl]amino]acetyl]amino]acetic acid Chemical compound OC(=O)CNC(=O)CNC(=O)CNC(=O)CS RXACEEPNTRHYBQ-UHFFFAOYSA-N 0.000 claims description 2
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 claims description 2
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims description 2
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 claims description 2
- 239000000178 monomer Substances 0.000 claims description 2
- 229910052713 technetium Inorganic materials 0.000 claims description 2
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 abstract description 10
- 238000001727 in vivo Methods 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 5
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 238000009206 nuclear medicine Methods 0.000 abstract description 3
- 239000003068 molecular probe Substances 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 85
- 238000013170 computed tomography imaging Methods 0.000 description 85
- 230000002285 radioactive effect Effects 0.000 description 56
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 42
- 238000006243 chemical reaction Methods 0.000 description 34
- 241000699660 Mus musculus Species 0.000 description 33
- 238000011580 nude mouse model Methods 0.000 description 33
- 238000009826 distribution Methods 0.000 description 31
- 208000014018 liver neoplasm Diseases 0.000 description 29
- 201000007270 liver cancer Diseases 0.000 description 27
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 24
- 239000007787 solid Substances 0.000 description 24
- 208000026310 Breast neoplasm Diseases 0.000 description 22
- 239000000047 product Substances 0.000 description 21
- 206010006187 Breast cancer Diseases 0.000 description 17
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 17
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 16
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 16
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 16
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 16
- 238000001819 mass spectrum Methods 0.000 description 16
- 201000002528 pancreatic cancer Diseases 0.000 description 16
- 208000008443 pancreatic carcinoma Diseases 0.000 description 16
- 230000015572 biosynthetic process Effects 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 238000003786 synthesis reaction Methods 0.000 description 15
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 14
- 206010008342 Cervix carcinoma Diseases 0.000 description 14
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 14
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 14
- 201000010881 cervical cancer Diseases 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 239000007791 liquid phase Substances 0.000 description 12
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 11
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 10
- 238000010438 heat treatment Methods 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 206010009944 Colon cancer Diseases 0.000 description 9
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- 238000004949 mass spectrometry Methods 0.000 description 9
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 8
- 239000007997 Tricine buffer Substances 0.000 description 8
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 8
- 238000001035 drying Methods 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- HBBSDZXXUIHKJE-UHFFFAOYSA-N 6-hydrazinylpyridine-3-carboxylic acid Chemical compound NNC1=CC=C(C(O)=O)C=N1 HBBSDZXXUIHKJE-UHFFFAOYSA-N 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- SILCDLWESNHZKB-UHFFFAOYSA-L disodium 4-hydroxy-4-oxobutanoate Chemical compound [Na+].[Na+].OC(=O)CCC([O-])=O.OC(=O)CCC([O-])=O SILCDLWESNHZKB-UHFFFAOYSA-L 0.000 description 6
- 239000000975 dye Substances 0.000 description 6
- 238000010828 elution Methods 0.000 description 6
- 201000005202 lung cancer Diseases 0.000 description 6
- 208000020816 lung neoplasm Diseases 0.000 description 6
- VATYWCRQDJIRAI-UHFFFAOYSA-N p-aminobenzaldehyde Chemical compound NC1=CC=C(C=O)C=C1 VATYWCRQDJIRAI-UHFFFAOYSA-N 0.000 description 6
- 239000008362 succinate buffer Substances 0.000 description 6
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 6
- 238000000967 suction filtration Methods 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- -1 Triphenyl sodium phosphate tribasic Chemical compound 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- SNDPXSYFESPGGJ-UHFFFAOYSA-N 2-aminopentanoic acid Chemical compound CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 4
- XWHHYOYVRVGJJY-QMMMGPOBSA-N 4-fluoro-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(F)C=C1 XWHHYOYVRVGJJY-QMMMGPOBSA-N 0.000 description 4
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 4
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 4
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 201000007983 brain glioma Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 235000013922 glutamic acid Nutrition 0.000 description 4
- 239000004220 glutamic acid Substances 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000012217 radiopharmaceutical Substances 0.000 description 4
- 229940121896 radiopharmaceutical Drugs 0.000 description 4
- 230000002799 radiopharmaceutical effect Effects 0.000 description 4
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 3
- DKIDEFUBRARXTE-UHFFFAOYSA-N 3-mercaptopropanoic acid Chemical compound OC(=O)CCS DKIDEFUBRARXTE-UHFFFAOYSA-N 0.000 description 3
- UAWMVMPAYRWUFX-UHFFFAOYSA-N 6-Chloronicotinic acid Chemical compound OC(=O)C1=CC=C(Cl)N=C1 UAWMVMPAYRWUFX-UHFFFAOYSA-N 0.000 description 3
- 206010052399 Neuroendocrine tumour Diseases 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 208000019065 cervical carcinoma Diseases 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000013399 early diagnosis Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 3
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 208000016065 neuroendocrine neoplasm Diseases 0.000 description 3
- 201000011519 neuroendocrine tumor Diseases 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 229940074404 sodium succinate Drugs 0.000 description 3
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000004611 spectroscopical analysis Methods 0.000 description 3
- 239000001384 succinic acid Substances 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 3
- 229910021642 ultra pure water Inorganic materials 0.000 description 3
- 239000012498 ultrapure water Substances 0.000 description 3
- RFFLAFLAYFXFSW-UHFFFAOYSA-N 1,2-dichlorobenzene Chemical compound ClC1=CC=CC=C1Cl RFFLAFLAYFXFSW-UHFFFAOYSA-N 0.000 description 2
- FVIIUVNKCOEULE-UHFFFAOYSA-N 2,2,3-trimethyl-1,3-dihydroindole-5-sulfonic acid Chemical compound CC1C2=C(C=CC(=C2)S(=O)(=O)O)NC1(C)C FVIIUVNKCOEULE-UHFFFAOYSA-N 0.000 description 2
- SYBYTAAJFKOIEJ-UHFFFAOYSA-N 3-Methylbutan-2-one Chemical compound CC(C)C(C)=O SYBYTAAJFKOIEJ-UHFFFAOYSA-N 0.000 description 2
- ACWBBAGYTKWBCD-ZETCQYMHSA-N 3-chloro-L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(Cl)=C1 ACWBBAGYTKWBCD-ZETCQYMHSA-N 0.000 description 2
- UQTZMGFTRHFAAM-ZETCQYMHSA-N 3-iodo-L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(I)=C1 UQTZMGFTRHFAAM-ZETCQYMHSA-N 0.000 description 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 2
- QUOGESRFPZDMMT-UHFFFAOYSA-N L-Homoarginine Natural products OC(=O)C(N)CCCCNC(N)=N QUOGESRFPZDMMT-UHFFFAOYSA-N 0.000 description 2
- QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical compound OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 description 2
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 2
- 108010077895 Sarcosine Proteins 0.000 description 2
- 239000000298 carbocyanine Substances 0.000 description 2
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 229960002591 hydroxyproline Drugs 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000002603 single-photon emission computed tomography Methods 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- AQTUACKQXJNHFQ-LURJTMIESA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanedioic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CCC(O)=O AQTUACKQXJNHFQ-LURJTMIESA-N 0.000 description 1
- IOMZCWUHFGMSEJ-UHFFFAOYSA-N 4-(azaniumylamino)benzenesulfonate Chemical compound NNC1=CC=C(S(O)(=O)=O)C=C1 IOMZCWUHFGMSEJ-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000008558 metabolic pathway by substance Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- VYFPSYVVFFFYBF-UHFFFAOYSA-N sodium;triphenylphosphane Chemical compound [Na].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 VYFPSYVVFFFYBF-UHFFFAOYSA-N 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229910000406 trisodium phosphate Inorganic materials 0.000 description 1
- 235000019801 trisodium phosphate Nutrition 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0056—Peptides, proteins, polyamino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention discloses an application of tumor targeting polypeptide. The series of high affinity polypeptides of the invention can be specifically combined with a plurality of tumor cells, and can be used for optical imaging and nuclear medicine imaging of malignant tumors by utilizing the high affinity characteristic. The high-affinity polypeptide-coupled fluorescent dye can be used as a tumor specific targeting molecular probe, is expected to achieve the effect of accurately positioning a tumor boundary, can bring real-time performance to image navigation before and during operation, and has the advantage of improving the operation accuracy. The series of polypeptides can also be coupled with radionuclide to detect malignant tumors in real time in vivo so as to achieve the purpose of disease diagnosis or treatment.
Description
Description of the different cases
The application is divided application with application date of 2020, 05 and 11, application number of 202010392677X, and name of the invention being tumor targeting polypeptide and application thereof.
Technical Field
The invention belongs to the technical field of bioengineering pharmacy and the field of protein polypeptide drugs and biomedical engineering, and particularly relates to a tumor targeting polypeptide and application thereof.
Background
Tumors have become the chief culprit threatening human health and life, and therefore, early diagnosis of tumors and effective treatment of tumors are very important and urgent. For tumors, the conventional image diagnosis technologies mainly include B-ultrasound, CT and MRI, and the image diagnosis technologies achieve diagnosis results by displaying the function change of tissues, have good application value, but have certain defects in differential diagnosis, whole body staging and early curative effect evaluation. Undeniably, screening and optimizing the polypeptide targeting the tumor is a new way, can develop novel molecular imaging drugs for the diagnosis, staging and operation guidance of the tumor, can discover more tiny focuses, and achieves the purpose of early diagnosis.
The cyanine dye has the advantages of small molecular weight, low toxicity, wide wavelength adjustable range, large molar extinction coefficient and the like, so that the cyanine dye is widely applied to the field of fluorescent labeling. The structure of the cyanine dye is modified to be connected with a reactive group with activity, and then the reactive group reacts with amino or carboxyl of a specific target molecule such as an antibody, a protein, a short peptide, a small molecule and the like to form a stable covalent bond, so that a probe with the specific target molecule is formed to perform fluorescent molecule living body imaging, and the fluorescent molecule living body imaging method is an important application of the near-infrared fluorescent dye. Single-Photon emission computed tomography (SPECT-CT) is a novel nuclear medicine imaging technology developed in recent 20 years and popularized clinically, mainly utilizes short-half-life radionuclide to mark a ligand with specific targeting for tracing and imaging, can display information such as substance metabolism, cell proliferation and receptor distribution in vivo, and is used for diagnosis of diseases and research of human body life activities. Therefore, specifically targeted ligands are critical for fluorescence imaging as well as radionuclide imaging.
Based on the consideration, the applicant designs a novel tumor targeting polypeptide, the polypeptide can specifically target tumors, and the coupled fluorescent dye can be used for optical imaging to assist doctors in accurately positioning tumor boundaries in the operation when molecular imaging operation navigation equipment is used, so that the aim of accurately cutting off the tumors is fulfilled, the wound on a patient is reduced, and the risk of postoperative recurrence is reduced. In addition, the targeting polypeptide can be coupled with radionuclide to carry out nuclide imaging, so as to achieve the purposes of early diagnosis and treatment of tumors.
Disclosure of Invention
The invention aims at providing several polypeptides with novel structure and tumor specificity target and sequences thereof;
the invention also aims to provide a preparation method of several tumor-specific targeted fluorescent probes;
the invention also aims to provide a preparation method of a plurality of tumor-specific targeting radioactive probes;
it is a further object of the invention to provide several of the described probes for use in optical and SPECT imaging.
A tumor-specific targeting polypeptide selected from any one of the following polypeptides:
YQGA-2:D-Asp-Arg-Val-Tyr-Ile-His-Pro-D-Phe
YQGA-3:D-Asp-homoArg-Nva-(3-I-Tyr)-Nle-His-Hyp-(4-F-Phe)
YQGA-4:[Sar]-homoArg-Nva-(3-Cl-Tyr)-Nle-His-Hyp-Nle
YQGA-5:D-Asp-Arg-Val-Tyr-NH 2
YQGA-6:D-Asp-homoArg-Nva-Tyr-NH 2
YQGA-7:D-Asp-homoArg-Nva-(4-OCH 3 -Phe)
YQGA-8:Asp-homoArg-Nva-Tyr-NH 2
YQGA-9: Mpa-D-Asp-Arg-Val-Tyr-Lys-Cys, wherein MPA-Cys disulfide bonds form a ring;
YQGA-10: Mpa-D-Asp-Arg-Val-Tyr-Cys-Lys, wherein the MPA-Cys disulfide bond forms a ring;
YQGA-11: beta-Ala-D-Asp-Arg-Val-Tyr-Lys-Asp (beta-Ala amino group and Asp backbone carboxyl group forming a ring)
YQGA-12: beta-Ala-D-Asp-Arg-Val-Tyr-Asp-Lys (beta-Ala amino and Asp backbone carboxyl forming a ring)
Wherein: D-Asp: d-aspartic acid; homoArg: homoarginine; nva: norvaline; nle: norleucine; hyp: a hydroxyproline; 4-F-Phe: 4-fluoro-phenylalanine; 4-OCH 3 -Phe: 4-fluoro-phenylalanine; [ Sar)]: n-methylglycine; 3-Cl-Try: 3-chloro-tyrosine; 3-I-Try: 3-iodo-tyrosine; mpa: 3-mercaptopropionic acid.
The application of the tumor-specific targeted polypeptide in preparing a tumor diagnosis reagent is preferably the application in preparing a tumor diagnosis imaging agent; further preferably in the preparation of precise tumor boundary positioning and intraoperative image navigation imaging reagents or radionuclide imaging reagents; the tumor-specific targeting polypeptide is selected from any one of the following polypeptides:
YQGA-1:Asp-Arg-Val-Tyr-Ile-His-Pro-Phe
YQGA-2:D-Asp-Arg-Val-Tyr-Ile-His-Pro-D-Phe
YQGA-3:D-Asp-homoArg-Nva-(3-I-Tyr)-Nle-His-Hyp-(4-F-Phe)
YQGA-4:[Sar]-homoArg-Nva-(3-Cl-Tyr)-Nle-His-Hyp-Nle
YQGA-5:D-Asp-Arg-Val-Tyr-NH 2
YQGA-6:D-Asp-homoArg-Nva-Tyr-NH 2
YQGA-7:D-Asp-homoArg-Nva-(4-OCH 3 -Phe)
YQGA-8:Asp-homoArg-Nva-Tyr-NH 2
YQGA-9: Mpa-D-Asp-Arg-Val-Tyr-Lys-Cys, wherein the MPA-Cys disulfide bond forms a ring;
YQGA-10: Mpa-D-Asp-Arg-Val-Tyr-Cys-Lys, wherein the MPA-Cys disulfide bond forms a ring;
YQGA-11: beta-Ala-D-Asp-Arg-Val-Tyr-Lys-Asp (beta-Ala amino group and Asp backbone carboxyl group forming a ring)
YQGA-12: beta-Ala-D-Asp-Arg-Val-Tyr-Asp-Lys (beta-Ala amino and Asp backbone carboxyl forming a ring)
Wherein: D-Asp: d-aspartic acid; homoArg: homoarginine; nva: norvaline; nle: norleucine; hyp: hydroxyproline; 4-F-Phe: 4-fluoro-phenylalanine; 4-OCH 3 -Phe: 4-fluoro-phenylalanine; [ Sar)]: n-methylglycine; 3-Cl-Try: 3-chloro-tyrosine; 3-I-Try: 3-iodo-tyrosine; mpa: 3-mercaptopropionic acid.
A polypeptide compound with tumor-targeted fluorescence imaging function contains a polypeptide for targeting tumor and an infrared fluorescent dye structure for optical imaging, and the structural general formula of the polypeptide compound is shown as the following formula (I):
the structure of the polypeptide contains a polypeptide R for targeting tumor, a near-infrared fluorescent dye structure MPA for optical imaging and a connecting agent L which can increase the distance between the targeting polypeptide and the near-infrared fluorescent dye and adjust the in vivo pharmacokinetic characteristic.
The polypeptide R is selected from any one of the above tumor-specific targeting polypeptides YQGA-X (X ═ 1-12) of the present invention.
The drug linking agent L is selected from L1, L2, L3 and L4 shown in a structural formula (II);
the invention also provides a method for preparing the polypeptide fluorescent probe, which comprises the following steps:
1) synthesis of near-infrared fluorescent dye MPA
Glacial acetic acid, p-hydrazino benzenesulfonic acid, methyl isopropyl ketone and sodium acetate are mixed and reacted, and a product 2,2, 3-trimethyl [3H ] -indole-5-sulfonic acid is obtained after purification; and adding o-dichlorobenzene into the mixture of 2,2, 3-trimethyl [3H ] -indole-5-sulfonic acid and 1, 3-propane sulfonic lactone to prepare the 2,2, 3-trimethyl-5-sulfonic acid-1- (3-sulfonic acid-propyl) - [3H ] -indole. And then reacting the product with N- [ (3- (anilomethylene) -2-chloro-1-cyclohexen-1-yl) methyl ] -aniline monohydrochloride to obtain green carbocyanine dye, and finally reacting the carbocyanine dye with mercaptopropionic acid and triethylamine to prepare a liquid phase, and separating and purifying the liquid phase to obtain the water-soluble near-infrared dye MPA.
2) Synthesis of MPA-L-YQGA-X (X. sub.1-12)
And dissolving the separated and purified near-infrared dye MPA and L-YQGA-X (X ═ 1-12) polypeptide synthesized by a solid phase in dimethyl sulfoxide, adding a proper amount of N, N-Diisopropylethylamine (DIPEA), reacting at room temperature overnight, and after the reaction is finished, purifying and separating a prepared liquid phase to obtain the target fluorescent compound.
The invention relates to the application of the polypeptide compound with the tumor-targeted fluorescence imaging function in the preparation of tumor diagnostic reagents; preferably in the preparation of an imaging agent for tumor diagnosis; further preferably in the preparation of a precise localization of tumor boundaries and intra-operative image-navigation imaging agent or in the preparation of a radionuclide imaging agent.
On the basis, the invention further provides a radionuclide probe which is a monomeric polypeptide complex and a dimeric polypeptide complex labeled by radionuclide technetium, and the structural formulas are shown as (III), (IV) and (V):
the monomer-form targeting complex is simpler to prepare than a dimer form, and the dimer structure of the targeting complex contains polypeptide YQGA-X for targeting tumors, a bifunctional chelating agent 6-hydrazinopyridine-3-formic acid (HYNIC) for radioactive labeling, a support (3L-E) for connecting glutamic acid with a three-molecule connecting agent L, and a connecting agent L which is used for increasing the distance between the targeting polypeptide and a radionuclide ligand N-tris (hydroxymethyl) methylglycine (Tricine) and triphenylphosphine sodium salt of tri-metaphenylphosphine sodium sulfonate (TPPTS) and adjusting in vivo pharmacokinetic characteristics, wherein L is selected from L1, L2, L3 and L4. Wherein the bifunctional chelating agent is modified, e.g. replaced by a bifunctional chelating agent such as DOTA, NOTA, MAG 3 Or DTPA, optionally with radionuclides 99m Radionuclides other than Tc, e.g. 68 Ga, 64 Cu, 67 Ga, 90 Y, 111 In or 177 Lu is used for diagnosis or treatment of diseases.
The invention also provides a method for preparing the monomer and dimer radionuclide probes, which comprises the following steps:
1) synthesis of bifunctional chelating agent HYNIC-L-NHS
Adding 6-chloronicotinic acid and 80% hydrazine hydrate into ethanol, heating and refluxing for reaction, performing rotary evaporation on the solvent under reduced pressure after the reaction is finished, adding the obtained viscous substance into distilled water, adjusting the pH value to be about 5.5, separating out solid, performing suction filtration and drying to obtain yellow solid, and determining the product as 6-hydrazinonicotinic acid through ESI-MS mass spectrum and nuclear magnetic hydrogen spectrum. Adding the obtained 6-hydrazinonicotinic acid and p-aminobenzaldehyde into dimethyl sulfoxide (DMSO), heating for reaction for 5-6 hours, adding into water for precipitation after the reaction is finished, performing suction filtration to obtain a solid, adding the dried solid, 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDCI) and N-hydroxysuccinimide (NHS) into the DMSO for reaction at room temperature, adding into water for precipitation after the reaction is finished, purifying the solid through a silica gel column, determining the solid as an intermediate HYNIC-NHS through ESI-MS mass spectrometry and nuclear magnetic hydrogen spectrometry, reacting the intermediate with a linking agent L under an alkaline condition, finally activating with activating agents EDCI and NHS, and purifying to obtain a HYNIC-L-NHS solid for later use.
2) Synthesis of scaffold (2L-E)
Dissolving a proper amount of Boc-glutamic acid in DMSO, adding 2 times of molar amount of EDCI and NHS, heating at 60 ℃ for 30min, analyzing the generation of glutamic acid double-activated ester by HPLC, adding 2 times of molar amount of linker L and 3 times of molar amount of DIPEA, heating at 60 ℃ for 30min, analyzing 2 PEG by HPLC 4 The molecule is connected with glutamic acid, then equal volume of TFA is added to react at room temperature overnight to remove Boc protection, and finally the crude product is frozen and dried for standby after being separated by a preparation liquid phase.
3) Synthesis of intermediate 3L-E-HYNIC-NHS
Dissolving the prepared stent 2L-E in DMSO, adding HYNIC-L-NHS with the same molar weight, adding 3 times of DIPEA, reacting at room temperature for 2 hours, separating and purifying the prepared liquid phase after the reaction is finished, confirming the target compound by mass spectrometry, activating the purified product by EDCI and NHS, and purifying to obtain 3L-E-HYNIC-NHS for later use.
4)(YQGA-X) 2 Synthesis of (E) -3L-HYNIC
Dissolving the purified intermediate 3L-E-HYNIC-NHS in DMSO, adding 0.5 molar of targeting peptide YQG-X, then adding 2 molar of DIPEA, reacting at room temperature for 1 hour, and after the reaction is finished, separating and purifying by a preparation liquid phase and confirming by mass spectrometry.
5) Radioactive probe 99m Tc-HYNIC-3L-E-(YQGA-X) 2 Synthesis of (2)
TPPTS (Triphenyl sodium phosphate tribasic) solution with the concentration of 100.0mg/mL, Tricine (trimethylglycine) with the concentration of 130.0mg/mL, succinic acid-sodium succinate buffer solution with the concentration of 102.4mg/mL (wherein the succinic acid is 77.0 mg, and the sodium succinate is 25.4mg) are respectively prepared, and 10.0uL of TPPTS solution, 10.0uL of Tricine solution, 10.0uL of succinic acid-sodium succinate buffer solution and 10.0uL (1.0mg/mL) of HYNIC-3L-E- (YQGA-X) are respectively taken 2 Mixing in penicillin bottle, and adding 10mCi Na 99m TcO 4 Heating in a metal bath at 100 ℃ for 20 minutes, cooling to room temperature after the reaction is finished, respectively preparing polypeptide radiopharmaceuticals, and analyzing and identifying the product by an Agilent ZORBAX SB-Aq analytical column.
The radionuclide probe is applied to the preparation of tumor diagnostic reagents; preferably in the preparation of an imaging agent for tumor diagnosis; further preferably in the preparation of precise localization of tumor boundaries and intraoperative image-guided imaging agents or in the preparation of radionuclide imaging agents.
The polypeptide compound can be specifically targeted to a tumor part, has good uptake and retention capacity at the tumor part, has a high target/non-target ratio, is suitable for being used as a fluorescent tumor imaging agent, a radionuclide imaging agent and a therapeutic agent, and can be used for preparing an optical imaging medicament for image navigation and accurate positioning of tumor boundaries in a tumor operation.
Compared with the prior art, the novel polypeptide and the fluorescent and radionuclide probes constructed by the series of polypeptides have the beneficial effects that:
1. the YQGA-X series of polypeptides discovered by the invention are low molecular weight polypeptides, and several or more amino acids of the series of polypeptides are modified unnatural amino acids, and the introduction of the unnatural amino acids can greatly improve the stability of the series of polypeptides in vivo.
2. The YQGA-X series of polypeptides are proved to have excellent imaging effect on various tumors including liver cancer, lung cancer, breast cancer, pancreatic cancer, colorectal cancer, cervical cancer and the like through in vivo optics and radionuclide imaging results. The probe constructed by the series of polypeptides can specifically target the property of a tumor part, so that nuclear medicine diagnosis and treatment of malignant tumors and optical imaging guidance of surgeons for operation navigation can be possibly realized, and accurate excision of a focus is achieved.
3. The invention uses the near-infrared fluorescent dye MPA with more ideal stability and water solubility as an optical imaging group, and improves the pharmacokinetics of the medicament in vivo.
4. In the invention, a plurality of water-soluble PEG are introduced 4 Or PEG 6 Molecules to further improve the pharmacokinetic properties, in particular the kinetics of clearance from non-tumor tissues.
5. In the invention, HYNIC is used as a bifunctional chelating agent, and Tricine and TPPTS are simultaneously used as synergistic ligands, so that " 99m Tc-HYNIC nucleus has better in vivo and in vitro stability.
The invention is further explained with reference to the drawings and the embodiments.
Drawings
FIG. 1 shows the fluorescent compound MPA-PEG prepared in example 1 4 Fluorescence imaging of YQGA-1 in hepatoma HepG2 tumor-bearing mice.
FIG. 2 is prepared as in example 2 99m Tc-HYNIC-PEG 4 SPECT-CT imaging of YQGA-1 in liver cancer HepG2 tumor-bearing mice (A) and brain glioma U87MG tumor-bearing mice (B).
FIG. 3 shows the radioactive compound prepared in example 4 99m Tc-SPECT-CT imaging of HYNIC-YQGA-2 in tumor-bearing mice: a is SPECT-CT imaging in a liver cancer HepG2 tumor-bearing mouse, B is SPECT-CT imaging in a cervical cancer HeLa tumor-bearing mouse, C is SPECT-CT imaging in a breast cancer MCF-7 tumor-bearing mouse, and D is SPECT-CT imaging in a liver cancer MHCC97-H tumor-bearing mouse.
FIG. 4 shows the radioactive compound prepared in example 8 99m Tc-HYNIC-PEG 4 SPECT-CT imaging of YQGA-3 in hepatoma HepG2 tumor-bearing mice.
FIG. 5 shows the radioactive compound prepared in example 9 99m Tc-HYNIC-PEG 4 SPECT-CT imaging of YQGA-4 in hepatoma HepG2 tumor-bearing mice.
FIG. 6 shows the radioactive compound prepared in example 10 99m Tc-HYNIC-PEG 4 SPECT-CT imaging of YQGA-5 in tumor-bearing mice: SPECT-CT imaging of A in liver cancer HepG2 tumor-bearing mice; b, SPECT-CT imaging in a liver cancer MHCC97-H tumor-bearing mouse; c SPECT-CT imaging in a cervical cancer HeLa tumor-bearing mouse; SPECT-CT imaging in breast cancer MCF-7 tumor-bearing mice.
FIG. 7 shows the radioactive compound prepared in example 14 99m Tc-HYNIC-PEG 4 SPECT-CT imaging of YQGA-6 in tumor-bearing mice: a is in liver cancer HepG 2; b is SPECT-CT imaging in a cervical cancer HeLa tumor-bearing mouse; c is SPECT-CT imaging in lung cancer A549 tumor-bearing mice; d is SPECT-CT imaging in a breast cancer MCF-7 tumor-bearing mouse; SPECT-CT imaging in mice bearing SW1990 tumors in pancreatic cancer; f is SPECT-CT imaging in colorectal cancer HT29 tumor-bearing mice; g is SPECT-CT imaging in neuroendocrine tumor BON-1 tumor-bearing mice.
FIG. 8 shows the radioactive compound prepared in example 14 99m Tc-HYNIC-YQGA-6 in-situ colorectal cancer tumor-bearing mouse 1h18min SPECT-CT imaging result
FIG. 9 shows the radioactive compound prepared in example 22 99m Tc-HYNIC-3PEG 4 -E-(YQGA-6) 2 SPECT-CT imaging in pancreatic cancer CFPAC-1 tumor-bearing mice.
FIG. 10 is a fluorescence image of the fluorescent compound MPA-Aca-YQGA-6 prepared in example 23 in tumor-bearing mice: a is fluorescence imaging in a liver cancer HepG2 tumor-bearing mouse; b is fluorescence imaging in breast cancer MCF-7 tumor-bearing mice.
FIG. 11 shows the radioactive compound prepared in example 25 99m Tc-HYNIC-PEG 4 SPECT-CT imaging of YQGA-7 in mice bearing HeLa tumors of cervical carcinoma.
FIG. 12 shows the radioactive compound prepared in example 26 99m Tc-HYNIC-PEG 4 SPECT-CT imaging of YQGA-8 in tumor-bearing mice: a is SPECT-CT imaging in a liver cancer HepG2 tumor-bearing mouse; b is SPECT-CT imaging in pancreatic cancer CFPAC-1 tumor-bearing mice.
FIG. 13 shows the radioactive compound prepared in example 28 99m Tc-HYNIC-PEG 4 SPECT-CT imaging of YQGA-9 in mice bearing MCF-7 tumors for breast cancer.
FIG. 14 shows the radioactive compound prepared in example 29 99m Tc-HYNIC-PEG 4 SPECT-CT imaging of YQGA-10 in mice bearing SW1190 tumors of pancreatic cancer.
FIG. 15 shows the radioactive compound prepared in example 30 99m Tc-HYNIC-PEG 4 SPECT-CT imaging of YQGA-11 in hepatoma HepG2 tumor-bearing mice.
FIG. 16 shows the radioactive compound prepared in example 31 99m Tc-HYNIC-PEG 4 SPECT-CT imaging of YQGA-12 in mice bearing MCF-7 tumors for breast cancer.
Detailed Description
The invention is further illustrated by the following specific examples and application examples: wherein the chemical substances used in the synthesis steps are all the existing substances or commercial products. The polypeptides involved in each example were synthesized by Hangzhou Guotu Biotech Co.
Fluorescent Compound MPA-PEG prepared in example 1 4 Fluorescence imaging of YQGA-1 in hepatoma HepG2 tumor-bearing mice
Weighing PEG synthesized by Commission Hangzhou Gutou Biotech Co 4 10mg of the YQGA-1 compound, 12.38mg of the purified MPA dye prepared was added to 200. mu.L of dimethyl sulfoxide (DMSO), followed by 2.3mg of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDCI) coupling agent and 3.82mg of N-hydroxysuccinimide (NHS),after mixing uniformly, adding 4.1mg of N, N-Diisopropylethylamine (DIPEA), reacting at room temperature overnight, and separating and purifying by using a preparation liquid phase after the reaction is finished, wherein the preparation liquid phase conditions are as follows: an Agilent 1220Infinity II series HPLC system was used with an Agilent ZORBAX SB-C18 semi-preparative column (9.4X 250mm, 5um) gradient elution for 60 minutes at a flow rate of 2mL/min, where mobile phase A was ultrapure water (0.01% TFA) and B was acetonitrile (0.01% TFA). The elution gradient was set as: 95% A and 5% B at 0-5 min, 80% A and 20% B at 15 min, 50% A and 50% B at 45 min, 5% A and 95% B at 60 min. The green product obtained finally is analyzed by analytical HPLC and ESI-MS mass spectrometry to confirm that the expected product MPA-PEG is obtained 4 -YQGA-1,ESI-MS:[M-3H] 3- 728.42 and [ M-4H] 4- 546.21. In the above preparation process, the PEG used in the step is replaced with a YQGA-X or L-YQGA-X polypeptide synthesized in a solid phase 4 YQGA-1 polypeptide, namely obtaining other fluorescent polypeptide compounds of the invention. Prepared compound MPA-PEG 4 YQGA-1 and prepared into a physiological saline solution (100nmol/mL), 0.1mL (about 10nmol) is respectively injected into tail veins of 3 nude mice (body weight about 22 g) with hepatoma HepG2 tumor, and optical signal acquisition is carried out at 1h, 2h, 4h, 8h, 10h and 12h after administration. The distribution of the probes in the mice and the enrichment in the tumor area were observed. Compound MPA-PEG 4 The imaging results of YQGA-1 in 3 tumor-bearing nude mice are basically consistent, and from the 2h imaging graph, it can be seen that the probe has significant uptake in the tumor, and it can be concluded that the probe is mainly metabolized through the kidney.
Radioactive compound prepared in example 2 99m Tc-HYNIC-PEG 4 SPECT-CT imaging of YQGA-1 in hepatoma HepG2 tumor-bearing mice
1) Bifunctional chelating agent HYNIC-PEG 4 Synthesis of-NHS
Adding 1g of 6-chloronicotinic acid and 2.0mL of 80% hydrazine hydrate into 10mL of ethanol, heating, refluxing and reacting for 4 hours, decompressing and rotary evaporating a solvent after the reaction is finished, adding the obtained sticky substance into distilled water, adjusting the pH value to be about 5.5, separating out a solid, carrying out suction filtration and drying to obtain 0.86g of a yellow solid, and determining the product to be 6-hydrazinonicotinic acid through ESI-MS mass spectrometry and nuclear magnetic hydrogen spectrometry. 0.86g of 6-hydrazinonicotinic acid was obtainedAnd 0.61g of p-aminobenzaldehyde are added into 3.0mL of dimethyl sulfoxide (DMSO), the mixture is heated and reacted for 5 to 6 hours, the mixture is added into water after the reaction is finished and separated out, and the solid 1.2g is obtained after suction filtration and drying. After drying 1.2g of the solid, 2.5g of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDCI) and 1.5g N-hydroxysuccinimide (NHS) were added into DMSO for reaction at room temperature, after the reaction was completed, water was added to the DMSO to precipitate a solid, the solid was purified by silica gel column and dried, 1.3g was weighed, and ESI-MS mass spectrometry and NMR spectrometry were carried out to determine the target product, ESI-MS: [ M + H ]]382.1508. This product was purified and 1 molar amount of PEG was added 4 And after the reaction is finished, adding EDCI and NHS with 2 times of molar weight for activation, performing freeze-drying after purification, and verifying the product as a target product by mass spectrum, ESI-MS: [ M + H ]]630.3 and [ M + Na]=652.3。
2) Purified 5mg intermediate HYNIC-PEG 4 NHS was dissolved in 0.3mL DMSO, then 5mg YQGA-1 was added, then 5.6mg DIPEA was added, and the reaction was performed at room temperature for 3 hours, and the product was separated and purified by preparative liquid phase after completion of the reaction to finally obtain 2.8mg of yellow solid, which was confirmed as a target product by mass spectrometry, ESI-MS: [ M +2H ]] 2+ 780.1 and [ M +3H ═] 3+ =520.5。
3) Radioactive compound 99m Tc-HYNIC-PEG 4 Synthesis of (E) -YQGA-1
TPPTS (Triphenyl sodium Tri-metaphosphate) solution with the concentration of 100.0mg/mL, Tricine (trimethylglycine) with the concentration of 130.0mg/mL, succinic acid-sodium succinate buffer solution with the concentration of 102.4mg/mL (wherein the succinic acid is 77.0 mg, and the sodium succinate is 25.4mg) are respectively prepared, 10.0uL TPPTS solution, 10.0uL Tricine solution, 10.0uL succinic acid-sodium succinate buffer solution and 10.0uL (1.0mg/mL) HYNIC-PEG are respectively taken 4 Mixing YQGA-1 in penicillin bottle, and adding 10mCi Na 99m TcO 4 Heating in 100 deg.C metal bath for 20 min, cooling to room temperature after reaction to obtain polypeptide radiopharmaceutical 99m Tc-HYNIC-PEG 4 YQGA-1, the product was analyzed and identified by Agilent ZORBAX SB-Aq analytical column. The HPLC method used was an Agilent 1220Infinity II series HPLC system equipped with an active on-line detector (Flow-RAM) and an Agilent ZORBAX SB-Aq analytical column (4.6X 250mm, 5um). Gradient elution is carried out for 45 minutes at a flow rate of 1mL/min, wherein the mobile phase A is ultrapure water (0.01% TFA) and the mobile phase B is acetonitrile (0.01% TFA). The elution gradient was set as: 95% A and 5% B at 0-5 min, 70% A and 30% B at 15 min, 65% A and 35% B at 20 min, 45% A and 55% B at 25 min, 5% A and 95% B at 45 min.
4) Radioactive compound 99m Tc-HYNIC-PEG 4 YQGA-1 is prepared into a physiological saline solution (3mCi/mL), 0.1mL (about 300 mu Ci) is respectively injected into the tail veins of 3 nude mice with liver cancer HepG2 tumor, and SPECT-CT signal acquisition is carried out at 0.5h, 1h, 2h, 3h and 4h after administration. The distribution of the radionuclide probes in the mice and the enrichment in the tumor area were observed. The 1.5h visualization result is shown as A in FIG. 2, from which it can be seen that the probe 99m Tc-HYNIC-PEG 4 YQGA-1 has obvious aggregation at the tumor site, which indicates that the probe can target liver cancer HepG2 tumor and is mainly metabolized out of body through kidney.
Radioactive compound prepared in example 3 99m Tc-HYNIC-PEG 4 SPECT-CT imaging of YQGA-1 in brain glioma U87MG tumor-bearing mice
Radioactive compound prepared in example 2 99m Tc-HYNIC-PEG 4 YQGA-1 and formulated into physiological saline solution (3mCi/mL), 0.1mL (about 300. mu. Ci) was injected into 3 brain glioma U87MG tumor-bearing nude mice, respectively, and SPECT-CT signal acquisition was performed at 0.5h, 1h, 2h and 4h after administration. The distribution of the probes in the mice and the enrichment in the tumor area were observed. The 1h SPECT-CT imaging result is shown as B in FIG. 2, and the probe can be seen to be targeted to recognize brain glioma U87 MG.
Radioactive compound prepared in example 4 99m SPECT-CT imaging of Tc-HYNIC-YQGA-2 in hepatoma HepG2 tumor-bearing mice
Reference example 2 preparation of Radioactive Compounds 99m Tc-HYNIC-YQGA-2(HYNIC-YQGA-2 verified by mass spectrum, ESI-MS: [ M + 2H)] 2+ 657.0 and [ M +3H] 3+ 438.5). In the same manner as in example 3 99m Tc-HYNIC-YQGA-2 is respectively injected into 3 liver cancer HepG2 tumor-bearing nude mice, and SPECT-CT signal acquisition is carried out 0.5h, 1h, 2h and 4h after administration. Observation ofDistribution of the probe in the mouse and enrichment in the tumor area. The 1h SPECT-CT imaging result is shown as A in figure 3, and the probe can be seen in the figure to identify the liver cancer HepG2 tumor in a targeted manner.
Radioactive compound prepared in example 5 99m SPECT-CT imaging of Tc-HYNIC-YQGA-2 in cervical carcinoma HeLa bearing mice
In the same manner as in example 3 99m Tc-HYNIC-YQGA-2 is respectively injected into 3 HeLa tumor-bearing nude mice with cervical cancer, and SPECT-CT signal acquisition is carried out at 0.5h, 1h, 2h and 4h after administration. The distribution of the probes in the mice and the enrichment in the tumor area were observed. The 1h SPECT-CT imaging result is shown as B in figure 3, and the probe can be seen in the figure to identify the HeLa tumor of the cervical cancer in a targeted manner.
Radioactive compound prepared in example 6 99m SPECT-CT imaging of Tc-HYNIC-YQGA-2 in breast cancer MCF-7 bearing mice
In the same manner as in example 3 99m Tc-HYNIC-YQGA-2 is respectively injected into 3 nude mice with liver cancer MCF-7 tumor, and SPECT-CT signal acquisition is carried out at 0.5h, 1h, 2h and 4h after administration. The distribution of the probes in the mice and the enrichment in the tumor area were observed. The 1h SPECT-CT imaging result is shown as C in figure 3, and the probe can be seen in the figure to be capable of identifying the MCF-7 tumor of the breast cancer in a targeted mode.
Radioactive compound prepared in example 7 99m SPECT-CT imaging of Tc-HYNIC-YQGA-2 in MHCC97-H tumor mice of liver cancer
In the same manner as in example 3 99m Tc-HYNIC-YQGA-2 is respectively injected into 3 liver cancer MHCC97-H tumor-bearing nude mice, and SPECT-CT signal acquisition is carried out 0.5H, 1H, 2H and 4H after administration. The distribution of the probes in the mice and the enrichment in the tumor area were observed. The 1H SPECT-CT imaging result is shown as D in FIG. 3, and the probe can be seen in the graph to be capable of identifying MHCC97-H tumor of liver cancer in a targeted mode.
Radioactive compound prepared in example 8 99m Tc-HYNIC-PEG 4 SPECT-CT imaging of YQGA-3 in hepatoma HepG2 tumor-bearing mice
Reference example 2 preparation of radioactive Compound 99m Tc-HYNIC-PEG 4 -YQGA-3(HYNIC-PEG 4 The mass spectrum of-YQGA-3 proves that ESI-MS shows that [ M +2H] 2+ 866.5 and [ M +3H] 3+ 577.6). In the same manner as in example 3 99m Tc-HYNIC-PEG 4 YQGA-3 was injected into 3 liver cancer HepG2 tumor-bearing nude mice, and SPECT-CT signal acquisition was performed at 0.5h, 1h, 2h and 4h after administration. The distribution of the probes in the mice and the enrichment in the tumor area were observed. The 1h SPECT-CT imaging result is shown in figure 4, and the probe can be seen in the figure to identify the liver cancer HepG2 tumor in a targeted manner.
Radioactive compound prepared in example 9 99m Tc-HYNIC-PEG 4 SPECT-CT imaging of YQGA-4 in hepatoma HepG2 tumor-bearing mice
Reference example 2 preparation of radioactive Compound 99m Tc-HYNIC-PEG 4 -YQGA-4(HYNIC-PEG 4 The mass spectrum of-YQGA-4 proves that ESI-MS shows that [ M +2H] 2+ 772.8 and [ M +3H] 3+ 515.2). In the same manner as in example 3 99m Tc-HYNIC-PEG 4 YQGA-4 was injected into 3 liver cancer HepG2 tumor-bearing nude mice, and SPECT-CT signal acquisition was performed at 0.5h, 1h, 2h and 4h after administration. The distribution of the probes in the mice and the enrichment in the tumor area were observed. The 1h SPECT-CT imaging result is shown in figure 5, and the probe can be seen in the figure to identify the liver cancer HepG2 tumor in a targeted manner.
Radioactive compound prepared in example 10 99m Tc-HYNIC-PEG 4 SPECT-CT imaging of YQGA-5 in hepatoma HepG2 tumor-bearing mice
Reference example 2 preparation of radioactive Compound 99m Tc-HYNIC-PEG 4 -YQGA-5(HYNIC-PEG 4 The mass spectrum of-YQGA-5 confirms that ESI-MS shows that [ M +2H ]] 2+ 509.6 and [ M +3H] 3+ 339.7). In the same manner as in example 3 99m Tc-HYNIC-PEG 4 YQGA-5 was injected into 3 liver cancer HepG2 tumor-bearing nude mice, and SPECT-CT signal acquisition was performed at 0.5h, 1h, 2h and 4h after administration. The distribution of the probes in the mice and the enrichment in the tumor area were observed. The 1.5h SPECT-CT imaging result is shown as A in figure 6, and the probe can be seen in the figure to identify the liver cancer HepG2 tumor in a targeted manner.
Example 11 preparation of radiationSex compound 99m Tc-HYNIC-PEG 4 SPECT-CT imaging of YQGA-5 in MHCC97-H hepatoma bearing mice
In the same manner as in example 3 99m Tc-HYNIC-PEG 4 YQGA-5 was injected into 3 mice bearing MHCC97-H tumor from liver cancer, and SPECT-CT signal acquisition was performed at 0.5H, 1H, 2H and 4H after administration. The distribution of the probes in the mice and the enrichment in the tumor area were observed. The 1H SPECT-CT imaging result is shown as B in FIG. 6, and the probe can be seen in the graph to be capable of identifying MHCC97-H tumor of liver cancer in a targeted mode.
Radioactive compound prepared in example 12 99m Tc-HYNIC-PEG 4 SPECT-CT imaging of YQGA-5 in mice bearing HeLa tumors for cervical cancer
In the same manner as in example 3 99m Tc-HYNIC-PEG 4 YQGA-5 is respectively injected into 3 HeLa tumor-bearing nude mice with cervical cancer, and SPECT-CT signal acquisition is carried out at 0.5h, 1h, 2h and 4h after administration. The distribution of the probes in the mice and the enrichment in the tumor area were observed. The 1h SPECT-CT imaging result is shown as C in figure 6, and the probe can be seen in the figure to identify the HeLa tumor of the cervical cancer in a targeted manner.
Radioactive compound prepared in example 13 99m Tc-HYNIC-PEG 4 SPECT-CT imaging of YQGA-5 in mice bearing MCF-7 tumors for breast cancer
In the same manner as in example 3 99m Tc-HYNIC-PEG 4 YQGA-5 was injected into 3 breast cancer MCF-7 tumor-bearing nude mice, and SPECT-CT signal acquisition was performed at 0.5h, 1h, 2h and 4h after administration. The distribution of the probes in the mice and the enrichment in the tumor area were observed. The 1h SPECT-CT imaging result is shown as D in FIG. 6, and the probe can be seen in the figure to identify the MCF-7 tumor of the breast cancer in a targeted manner.
Radioactive compound prepared in example 14 99m Tc-HYNIC-PEG 4 SPECT-CT imaging of YQGA-6 in hepatoma HepG2 tumor-bearing mice
Reference example 2 preparation of Radioactive Compounds 99m Tc-HYNIC-PEG 4 -YQGA-6(HYNIC-PEG 4 The mass spectrum of-YQGA-6 proves that ESI-MS shows that [ M +2H] 2+ 539.9 and [ M +3H] 3+ 360.3). As in example 3The same method is to 99m Tc-HYNIC-PEG 4 YQGA-6 was injected into 3 liver cancer HepG2 tumor-bearing nude mice, and SPECT-CT signal acquisition was performed at 0.5h, 1h, 2h and 4h after administration. The distribution of the probes in the mice and the enrichment in the tumor area were observed. The result of 1.5h SPECT-CT imaging is shown as A in figure 7, and the probe can be seen in the figure to identify the hepatoma HepG2 tumor in a targeted manner.
Radioactive compound prepared in example 15 99m Tc-HYNIC-PEG 4 SPECT-CT imaging of YQGA-6 in mice bearing HeLa tumors for cervical carcinoma
In the same manner as in example 3 99m Tc-HYNIC-PEG 4 YQGA-6 is respectively injected into 3 HeLa tumor-bearing nude mice with cervical cancer, and SPECT-CT signal acquisition is carried out at 0.5h, 1h, 2h and 4h after administration. The distribution of the probes in the mice and the enrichment in the tumor area were observed. The 1h SPECT-CT imaging result is shown as B in fig. 7, and the probe can be seen from the image to be capable of identifying the HeLa tumor of the cervical cancer in a targeted manner.
Radioactive compound prepared in example 16 99m Tc-HYNIC-PEG 4 SPECT-CT imaging of YQGA-6 in Lung cancer A549 tumor-bearing mice
In the same manner as in example 3 99m Tc-HYNIC-PEG 4 YQGA-6 was injected into 3 nude mice with lung cancer A549 tumor, and SPECT-CT signal acquisition was performed at 0.5h, 1h, 2h and 4h after administration. The distribution of the probes in the mice and the enrichment in the tumor area were observed. The 1h SPECT-CT imaging result is shown as C in FIG. 7, and the graph shows that the probe can target and identify the lung cancer A549 tumor.
Radioactive compound prepared in example 17 99m Tc-HYNIC-PEG 4 SPECT-CT imaging of YQGA-6 in mice bearing MCF-7 tumors for breast cancer
In the same manner as in example 3 99m Tc-HYNIC-PEG 4 YQGA-6 was injected into 3 lung cancer A549 tumor-bearing nude mice, and SPECT-CT signal acquisition was performed at 0.5h, 1h, 2h and 4h after administration. The distribution of the probes in the mice and the enrichment in the tumor area were observed. The 1h SPECT-CT imaging results are shown in D in FIG. 7, from which it can be seen that the probe can target breast cancer MCF-7 tumors.
Radioactive compound prepared in example 18 99m Tc-HYNIC-PEG 4 SPECT-CT imaging of YQGA-6 in mice bearing SW1990 tumors in pancreatic cancer
In the same manner as in example 3 99m Tc-HYNIC-PEG 4 YQGA-6 was injected into 3 pancreatic cancer SW1990 tumor-bearing nude mice, and SPECT-CT signal acquisition was performed at 0.5h, 1h, 2h and 4h after administration. The distribution of the probes in the mice and the enrichment in the tumor area were observed. The 1h SPECT-CT imaging result is shown as E in FIG. 7, and the probe can be seen in the figure to target and recognize SW1990 tumor of pancreatic cancer.
Radioactive compound prepared in example 19 99m Tc-HYNIC-PEG 4 SPECT-CT imaging of YQGA-6 in colorectal cancer HT29 tumor-bearing mice
In the same manner as in example 3 99m Tc-HYNIC-PEG 4 YQGA-6 was injected into 3 colorectal cancer HT29 tumor-bearing nude mice, and SPECT-CT signal acquisition was performed at 0.5h, 1h, 2h and 4h after administration. The distribution of the probes in the mice and the enrichment in the tumor area were observed. The 1h SPECT-CT imaging result is shown as F in FIG. 7, and the probe can be seen in the figure to be targeted and identify the colorectal cancer HT29 tumor.
Radioactive compound prepared in example 20 99m Tc-HYNIC-PEG 4 SPECT-CT imaging of YQGA-6 in neuroendocrine BON-1 tumor-bearing mice
In the same manner as in example 3 99m Tc-HYNIC-PEG 4 YQGA-6 was injected into 3 neuroendocrine tumor BON-1 tumor-bearing nude mice, and SPECT-CT signal acquisition was performed at 0.5h, 1h, 2h and 4h after administration. The distribution of the probes in the mice and the enrichment in the tumor area were observed. The 1h SPECT-CT imaging result is shown as G in figure 7, and the probe can be seen in the figure to be capable of identifying the tumor of the neuroendocrine tumor BON-1 in a targeted manner.
Radioactive compound prepared in example 21 99m Tc-HYNIC-PEG 4 SPECT-CT imaging of YQGA-6 in situ colorectal cancer bearing mice
In the same manner as in example 3 99m Tc-HYNIC-PEG 4 -YQGA-6 is respectively injected into 3 nude mice with tumor of carcinoma of orthotopic colorectal cancer, and is injected 0.5h, 1h and 18min after administration,SPECT-CT signal acquisition is carried out for 2h and 4 h. The distribution of the probe in the mouse and the enrichment in the tumor area were observed. The SPECT-CT imaging result at 1h and 18min is shown in figure 8, and the probe can be seen from the figure to identify colorectal cancer tumor in situ in a targeted manner.
Radioactive compound prepared in example 22 99m Tc-HYNIC-3PEG 4 -E-(YQGA-6) 2 SPECT-CT imaging in pancreatic cancer CFPAC-1 bearing mice
Prepared radiopharmaceuticals 99m Tc-HYNIC-3PEG 4 -E-(YQGA-6) 2 The synthesis steps are as follows:
1) bifunctional chelating agent HYNIC-PEG 4 Synthesis of-NHS
Adding 1g of 6-chloronicotinic acid and 2.0mL of 80% hydrazine hydrate into 10mL of ethanol, heating, refluxing and reacting for 4 hours, decompressing and rotary evaporating a solvent after the reaction is finished, adding the obtained sticky substance into distilled water, adjusting the pH value to be about 5.5, separating out a solid, carrying out suction filtration and drying to obtain 0.86g of a yellow solid, and determining the product to be 6-hydrazinonicotinic acid through ESI-MS mass spectrometry and nuclear magnetic hydrogen spectrometry. Adding 0.86g of the obtained 6-hydrazinonicotinic acid and 0.61g of p-aminobenzaldehyde into 3.0mL of dimethyl sulfoxide (DMSO), heating for reacting for 5-6 hours, adding into water after the reaction is finished, separating out, performing suction filtration, and drying to obtain 1.2g of solid. Adding the dried 1.2g of solid, 2.5g of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDCI) and 1.5g N-hydroxysuccinimide (NHS) into DMSO for reaction at room temperature, adding water to precipitate a solid after the reaction is finished, purifying the solid by a silica gel column, drying, weighing 1.3g, determining the solid as a target product through ESI-MS mass spectrum and nuclear magnetic hydrogen spectrum, and adding 1 molar amount of PEG after the product is purified 4 And after the reaction is finished, adding EDCI and NHS with 2 times of molar weight for activation, purifying and freeze-drying for later use.
2) Support (PEG) 4 ) 3 Synthesis of (E)
5.0g of t-butyloxycarbonyl (t-Butyloxy carbony) -protected glutamic acid, 8.3g of Dicyclohexylcarbodiimide (DCC) and 4.6g N-hydroxysuccinimide (NHS) were added to 100mL of Tetrahydrofuran (THF) as an organic solvent, stirred at room temperature overnight for dicarboxyl activation, after completion of the reaction, suction filtered, the filtrate was washed with THF without further washing after completion of the reactionStep (2) purification, adding into 50mL of dimethyl sulfoxide (DMSO) directly for dissolution, and adding 10g of PEG 4 Finally, 14.6g of DIPEA is added for reaction at room temperature for 2 hours, after the detection reaction is finished, 3.0mL of trifluoroacetic acid (TEA) is added into the reaction for removing the Boc protecting group, after the reaction is finished, separation and purification are carried out through a preparation liquid phase, and finally drying is carried out to obtain 7.8g of thick solid which is verified to be an expected target object (PEG) through mass spectrum 4 ) 2 -E。
3) Intermediate (PEG) 4 ) 3 Synthesis of-E-HYNIC-2 NHS
0.5g of the prepared scaffold (PEG) 4 ) 2 -E was dissolved in DMSO and 0.31g HYNIC-PEG was added 4 NHS, 0.32g DIPEA was added, the reaction was carried out at room temperature for 2 hours, EDCI and NHS were added for activation, and after completion of the reaction, the product was purified by preparative liquid phase separation and freeze-dried to give 0.34g of a yellow solid, which was confirmed by mass spectrometry as the desired target compound (PEG) 4 ) 3 -E-HYNIC-2NHS,ESI-MS:[M+2H] 2+ 675.5 and [ M +3H] 3+ =450.6。
4)HYNIC-3PEG 4 -E-(YQGA-6) 2 Synthesis of (2)
Purified 5mg of intermediate 3PEG 4 Dissolving E-HYNIC-2NHS in 0.3mL DMSO, adding 7.8 mg YQGA-6 after the reaction is finished, then adding 5.6mg DIPEA, reacting at room temperature for 3 hours, separating and purifying through a prepared liquid phase after the reaction is finished, finally obtaining 3.5mg yellow solid, confirming as a target product through mass spectrum, ESI-MS: [ M +3H ]] 3+ 825.7 and [ M +4H] 4+ =619.5。
5) 99m Tc-HYNIC-3PEG 4 -E-(YQGA-6) 2 Preparation of
TPPTS (Triphenyl sodium Tri-metaphosphate) solution with the concentration of 100.0mg/mL, Tricine (trimethylglycine) with the concentration of 130.0mg/mL, succinic acid-sodium succinate buffer solution with the concentration of 102.4mg/mL (wherein the succinic acid is 77.0 mg, and the sodium succinate is 25.4mg) are respectively prepared, 10.0uL TPPTS solution, 10.0uL Tricine solution, 10.0uL succinic acid-sodium succinate buffer solution and 10.0uL (1.0mg/mL) HYNIC-3PEG are respectively taken 4 -E-(YQGA-6) 2 Mixing in penicillin bottle, adding 10mCi Na 99m TcO 4 Heating in 100 deg.C metal bath for 20 min, cooling to room temperature after reaction to obtain polypeptide radiopharmaceutical 99m Tc-HYNIC-3PEG 4 -E-(YQGA-6) 2 And analyzing and identifying the product by an Agilent ZORBAX SB-Aq analytical column. The HPLC method used was an Agilent 1220Infinity II series HPLC system equipped with an active on-line detector (Flow-RAM) and an Agilent ZORBAX SB-Aq analytical column (4.6X 250mm, 5 um). Gradient elution is carried out for 45 minutes at a flow rate of 1mL/min, wherein the mobile phase A is ultrapure water (0.01% TFA) and the mobile phase B is acetonitrile (0.01% TFA). The elution gradient was set as: 95% A and 5% B at 0-5 min, 70% A and 30% B at 15 min, 65% A and 35% B at 20 min, 45% A and 55% B at 25 min, 5% A and 95% B at 45 min.
6) In the same manner as in example 3 99m Tc-HYNIC-3PEG 4 -E-(YQGA-6) 2 Respectively injecting the three drugs into 3 nude mice with pancreatic cancer CFPAC-1 tumor, and performing SPECT-CT signal acquisition 0.5h, 1h, 2h and 4h after drug administration. The distribution of the probes in the mice and the enrichment in the tumor area were observed. The result of 1h18min SPECT-CT imaging is shown in FIG. 9, and it can be seen that the probe can target and identify CFPAC-1 tumor of pancreatic cancer.
Fluorescence imaging of the fluorescent Compound MPA-Aca-YQGA-6 prepared in example 23 in hepatoma HepG2 tumor-bearing mice
The fluorescent compound MPA-Aca-YQGA-6 was prepared and formulated into a physiological saline solution (100nmol/mL) as in example 1, and 0.1mL (about 10nmol) was injected into the tail vein of 3 nude mice bearing tumor of HepG2 (body weight: about 22 g), respectively, and optical signal acquisition was performed at 1h, 2h, 4h, 8h, 10h and 12h after administration. The distribution of the probes in the mice and the enrichment in the tumor area were observed. The imaging results of the compound MPA-Aca-YQGA-6 in 3 tumor-bearing nude mice are basically consistent, and from the 2h imaging graph, the probe is obviously taken up in the tumor, and the probe is deduced to be mainly metabolized through the kidney (shown in A in FIG. 10).
Fluorescence imaging of the fluorescent Compound MPA-Aca-YQGA-6 prepared in example 24 in vivo in mice bearing MCF-7 tumor of Breast cancer
The fluorescent compound MPA-Aca-YQGA-6 was prepared and formulated into a physiological saline solution (100nmol/mL) as in example 1, and 0.1mL (about 10nmol) was injected into the tail vein of 3 nude mice bearing breast cancer MCF-7 (body weight: about 22 g), respectively, and optical signal acquisition was performed at 1h, 2h, 4h, 8h, 10h and 12h after administration. The distribution of the probes in the mice and the enrichment in the tumor area were observed. The imaging results of the compound MPA-Aca-YQGA-6 in 3 tumor-bearing nude mice are basically consistent, and from the 2h imaging graph (shown as B in FIG. 10), it can be seen that the probe has significant uptake in the tumor, and it can be concluded that the probe is mainly metabolized through the kidney.
Radioactive compound prepared in example 25 99m Tc-HYNIC-PEG 4 SPECT-CT imaging of YQGA-7 in mice bearing HeLa tumors for cervical cancer
Reference example 2 preparation of Radioactive Compounds 99m Tc-HYNIC-PEG 4 -YQGA-7(HYNIC-PEG 4 The mass spectrum of-YQGA-7 proves that ESI-MS shows that [ M +2H] 2+ 546.8 and [ M +3H] 3+ 364.5). In the same manner as in example 3 99m Tc-HYNIC-PEG 4 YQGA-7 is respectively injected into 3 HeLa tumor-bearing nude mice with cervical cancer, and SPECT-CT signal acquisition is carried out at 0.5h, 1h, 2h and 4h after administration. The distribution of the probes in the mice and the enrichment in the tumor area were observed. The 1h SPECT-CT imaging result is shown in figure 11, and the probe can be seen in the figure to identify the HeLa tumor of the cervical cancer in a targeted manner.
Radioactive compound prepared in example 26 99m Tc-HYNIC-PEG 4 SPECT-CT imaging of YQGA-8 in hepatoma HepG2 tumor-bearing mice
Preparation of Radioactive Compound in the same manner as in reference example 2 99m Tc-HYNIC-PEG 4 -YQGA-8 (HYNIC-PEG 4 The mass spectrum of-YQGA-8 proves that ESI-MS shows that [ M +2H] 2+ 539.8 and [ M +3H] 3+ 360.2). In the same manner as in example 3 99m Tc-HYNIC-PEG 4 YQGA-8 was injected into 3 liver cancer HepG2 tumor-bearing nude mice, and SPECT-CT signal acquisition was performed at 0.5h, 1h, 2h and 4h after administration. The distribution of the probes in the mice and the enrichment in the tumor area were observed. The 1h SPECT-CT imaging result is shown as A in figure 12, and the probe can be seen in the figure to identify the liver cancer HepG2 tumor in a targeted manner.
Radioactive compounds prepared in example 27 99m Tc-HYNIC-PEG 4 SPECT-CT imaging of YQGA-8 in mice bearing CFPAC-1 tumors of pancreatic cancer
In the same manner as in example 3 99m Tc-HYNIC-PEG 4 YQGA-8 was injected into 3 CFPAC-1 tumor-bearing nude mice with pancreatic cancer, and SPECT-CT signal acquisition was performed at 0.5h, 1h, 2h and 4h after administration. The distribution of the probes in the mice and the enrichment in the tumor area were observed. The 1h SPECT-CT imaging results are shown in FIG. 12, panel B, where it can be seen that the probe can target CFPAC-1 tumors that recognize pancreatic cancer.
Radioactive compound prepared in example 28 99m Tc-HYNIC-PEG 4 SPECT-CT imaging of YQGA-9 in mice bearing MCF-7 tumors for breast cancer
Reference example 2 preparation of Radioactive Compounds 99m Tc-HYNIC-PEG 4 -YQGA-9(HYNIC-PEG 4 The mass spectrum of-YQGA-9 proves that ESI-MS shows that [ M +2H] 2+ 691.1 and [ M +3H] 3+ 460.6). In the same manner as in example 3 99m Tc-HYNIC-PEG 4 YQGA-9 was injected into 3 breast cancer MCF-7 tumor-bearing nude mice, and SPECT-CT signal acquisition was performed at 0.5h, 1h, 2h and 4h after administration. The distribution of the probes in the mice and the enrichment in the tumor area were observed. The 1h SPECT-CT imaging result is shown in figure 13, and the probe can be seen in the figure to identify the MCF-7 tumor of the breast cancer in a targeted manner.
Radioactive compound prepared in example 29 99m Tc-HYNIC-PEG 4 SPECT-CT imaging of YQGA-10 in mice bearing SW1190 tumor of pancreatic cancer
Reference example 2 preparation of Radioactive Compounds 99m Tc-HYNIC-PEG 4 -YQGA-10 (HYNIC-PEG 4 The mass spectrum of-YQGA-10 proves that ESI-MS shows that [ M +2H] 2+ 691.1 and [ M +3H] 3+ 460.7). In the same manner as in example 3 99m Tc-HYNIC-PEG 4 YQGA-10 was injected into 3 pancreatic cancer SW1190 tumor-bearing nude mice, and SPECT-CT signal acquisition was performed at 0.5h, 1h, 2h and 4h after the administration. The distribution of the probes in the mice and the enrichment in the tumor area were observed. The 1h SPECT-CT imaging result is shown in FIG. 14, from which it can be seen that the probe can be targeted to the targetPancreatic adenocarcinoma SW1190 tumor.
Radioactive compounds prepared in example 30 99m Tc-HYNIC-PEG 4 SPECT-CT imaging of YQGA-11 in hepatoma HepG2 tumor-bearing mice
Reference example 2 preparation of Radioactive Compounds 99m Tc-HYNIC-PEG 4 -YQGA-11 (HYNIC-PEG 4 The mass spectrum of-YQGA-11 proves that ESI-MS shows that [ M +2H] 2+ 680.5 and [ M +3H] 3+ 453.6). In the same manner as in example 3 99m Tc-HYNIC-PEG 4 YQGA-11 was injected into 3 liver cancer HepG2 tumor-bearing nude mice, and SPECT-CT signal acquisition was performed at 0.5h, 1h, 2h and 4h after administration. The distribution of the probes in the mice and the enrichment in the tumor area were observed. The result of 1h SPECT-CT imaging is shown in FIG. 15, and the probe can be seen in the figure to identify the HepG2 tumor in a targeted manner.
Radioactive compound prepared in example 31 99m Tc-HYNIC-PEG 4 SPECT-CT imaging of YQGA-12 in mice bearing MCF-7 tumors for breast cancer
Reference example 2 preparation of radioactive Compound 99m Tc-HYNIC-PEG 4 -YQGA-12 (HYNIC-PEG 4 The mass spectrum of-YQGA-12 proves that ESI-MS shows that [ M +2H] 2+ 680.5 and [ M +3H] 3+ 453.5). In the same manner as in example 3 99m Tc-HYNIC-PEG 4 YQGA-12 was injected into 3 breast cancer MCF-7 tumor-bearing nude mice, and SPECT-CT signal acquisition was performed at 0.5h, 1h, 2h and 4h after administration. The distribution of the probes in the mice and the enrichment in the tumor area were observed. The 1h SPECT-CT imaging result is shown in figure 16, and the probe can be seen in the figure to identify the MCF-7 tumor of the breast cancer in a targeted way.
Claims (9)
1. The application of tumor specific targeting polypeptide in preparing tumor diagnosis reagent, wherein the tumor specific targeting polypeptide is selected from any one of the following polypeptides:
YQGA-1:Asp-Arg-Val-Tyr-Ile-His-Pro-Phe。
2. use according to claim 1, characterized in that the use of a tumor-specifically targeted polypeptide according to claim 1 for the preparation of an imaging agent for tumor diagnosis; preferably in the preparation of a reagent for precise localization of tumor boundaries and intra-operative image-guided imaging or for radionuclide imaging.
3. A polypeptide compound with tumor fluorescence targeting imaging function, which is characterized in that the structure contains the tumor specific targeting polypeptide YQGA-1 as claimed in claim 1 and an infrared fluorescent dye structure for optical imaging, and the general structural formula is shown as the following formula (I):
wherein R is selected from the tumor-specifically targeting polypeptide YQGA-1 of claim 1; l is selected from any one of four shown in the following II;
4. the use of the polypeptide compound having tumor-targeted fluorescence imaging function according to claim 3 for the preparation of a tumor diagnostic reagent.
5. The use according to claim 4, characterized in that the use of the polypeptide compound with tumor-targeted fluorescence imaging function according to claim 3 for the preparation of an imaging agent for tumor diagnosis; preferably in the preparation of a reagent for precise localization of tumor boundaries and intra-operative image-guided imaging or for radionuclide imaging.
6. A radionuclide probe characterized by being a polypeptide monomer complex as set forth in claim 1 or a polypeptide dimer complex as set forth in claim 1 labeled with radionuclide technetium; the structural formula is shown as (III), (IV) or (V):
or replacing the bifunctional chelating agent HYNIC in the formulas (III), (IV) and (V) with DOTA, NOTA and MAG 3 Or DTPA, radionuclide 99m Tc replacement by 68 Ga, 64 Cu, 67 Ga, 90 Y, 111 In or 177 Lu。
7. The radionuclide probe according to claim 6, characterized in that L is selected from any one or more of L1, L2, L3 or L4.
8. Use of the radionuclide probe according to claim 6 or 7 for the preparation of a tumor diagnostic reagent.
9. Use according to claim 8, characterized in that the radionuclide probe according to claim 6 or 7 is used for the preparation of an imaging agent for tumor diagnosis; preferably in the preparation of a reagent for precise localization of tumor boundaries and intra-operative image-guided imaging or for radionuclide imaging.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210359401.0A CN115068634A (en) | 2020-05-11 | 2020-05-11 | Application of tumor targeting polypeptide |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010392677.XA CN111558050B (en) | 2020-05-11 | 2020-05-11 | Tumor targeting polypeptide and application thereof |
CN202210359401.0A CN115068634A (en) | 2020-05-11 | 2020-05-11 | Application of tumor targeting polypeptide |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010392677.XA Division CN111558050B (en) | 2020-05-11 | 2020-05-11 | Tumor targeting polypeptide and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115068634A true CN115068634A (en) | 2022-09-20 |
Family
ID=72068047
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210359401.0A Pending CN115068634A (en) | 2020-05-11 | 2020-05-11 | Application of tumor targeting polypeptide |
CN202210360399.9A Active CN115006553B (en) | 2020-05-11 | 2020-05-11 | Polypeptide for preparing tumor diagnostic imaging agent and application thereof |
CN202210359385.5A Active CN114796528B (en) | 2020-05-11 | 2020-05-11 | Tumor-specific targeting polypeptides and uses thereof |
CN202010392677.XA Active CN111558050B (en) | 2020-05-11 | 2020-05-11 | Tumor targeting polypeptide and application thereof |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210360399.9A Active CN115006553B (en) | 2020-05-11 | 2020-05-11 | Polypeptide for preparing tumor diagnostic imaging agent and application thereof |
CN202210359385.5A Active CN114796528B (en) | 2020-05-11 | 2020-05-11 | Tumor-specific targeting polypeptides and uses thereof |
CN202010392677.XA Active CN111558050B (en) | 2020-05-11 | 2020-05-11 | Tumor targeting polypeptide and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (4) | CN115068634A (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113209315B (en) * | 2021-05-10 | 2022-11-04 | 中国医科大学 | Polypeptide probe for targeting tumor and application thereof |
CN113527416A (en) * | 2021-08-11 | 2021-10-22 | 南开大学 | Preparation method of nitroreductase responsive amino acid and tumor hypoxia fluorescent probe |
CN116712571B (en) * | 2021-12-16 | 2024-01-30 | 江西中医药大学 | Application of novel cyclic peptide in preparation of tumor diagnosis and/or treatment reagent |
CN114288426B (en) * | 2022-01-07 | 2023-08-01 | 江西中医药大学 | Application of eribante and derivatives thereof in preparation of tumor diagnosis and/or treatment reagent |
CN116407651B (en) * | 2023-05-12 | 2024-03-15 | 江西省人民医院 | Application of polypeptide MRWVYHPFQ in tumor diagnosis medicine |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101015689A (en) * | 2007-01-18 | 2007-08-15 | 中国药科大学 | Tumour polypeptide vaccine based on angiotensin II |
EP1970064A1 (en) * | 2007-03-12 | 2008-09-17 | Bayer Schering Pharma Aktiengesellschaft | Silicon-derivatives for pet-imaging |
CN108136039A (en) * | 2015-08-18 | 2018-06-08 | 阿斯皮利安治疗学股份有限公司 | For the composition of photoimmunotherapy, combination and correlation technique |
CN110845572A (en) * | 2019-11-28 | 2020-02-28 | 中国药科大学 | Tumor-targeted GRP (glass-fiber reinforced Polypropylene) analogue and application thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100589842C (en) * | 2001-01-19 | 2010-02-17 | 赛托斯生物技术公司 | Molecular antigen array |
ES2572975T3 (en) * | 2003-05-15 | 2016-06-03 | Ampio Pharmaceuticals, Inc. | Treatment of diseases mediated by T lymphocytes |
NO20034952D0 (en) * | 2003-11-06 | 2003-11-06 | Amersham Health As | Pharmaceutical compounds |
WO2009114461A2 (en) * | 2008-03-10 | 2009-09-17 | University Of Southern California | Angiotensin (1-7) dosage forms and uses thereof |
US10039846B2 (en) * | 2012-09-13 | 2018-08-07 | British Columbia Cancer Agency Branch | Compositions targeting bradykinin receptor B1 for medical imaging of cancer and other disorders |
-
2020
- 2020-05-11 CN CN202210359401.0A patent/CN115068634A/en active Pending
- 2020-05-11 CN CN202210360399.9A patent/CN115006553B/en active Active
- 2020-05-11 CN CN202210359385.5A patent/CN114796528B/en active Active
- 2020-05-11 CN CN202010392677.XA patent/CN111558050B/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101015689A (en) * | 2007-01-18 | 2007-08-15 | 中国药科大学 | Tumour polypeptide vaccine based on angiotensin II |
EP1970064A1 (en) * | 2007-03-12 | 2008-09-17 | Bayer Schering Pharma Aktiengesellschaft | Silicon-derivatives for pet-imaging |
CN108136039A (en) * | 2015-08-18 | 2018-06-08 | 阿斯皮利安治疗学股份有限公司 | For the composition of photoimmunotherapy, combination and correlation technique |
CN110845572A (en) * | 2019-11-28 | 2020-02-28 | 中国药科大学 | Tumor-targeted GRP (glass-fiber reinforced Polypropylene) analogue and application thereof |
Non-Patent Citations (2)
Title |
---|
AGOSTINO MOLTENI ET AL: "Potential Deployment of Angiotensin I Converting Enzyme Inhibitors and of Angiotensin II Type 1 and Type 2 Receptor Blockers in Cancer Chemotherapy", 《ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY》 * |
ROBERT HENNIG ET AL: "Multivalent targeting of AT1 receptors with angiotensin II-functionalized nanoparticles", 《JOURNAL OF DRUG TARGETING》 * |
Also Published As
Publication number | Publication date |
---|---|
CN114796528B (en) | 2023-11-10 |
CN115006553B (en) | 2024-01-05 |
CN114796528A (en) | 2022-07-29 |
CN115006553A (en) | 2022-09-06 |
CN111558050A (en) | 2020-08-21 |
CN111558050B (en) | 2022-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111558050B (en) | Tumor targeting polypeptide and application thereof | |
CN110845572B (en) | Tumor-targeted GRP (glass-fiber reinforced Polypropylene) analogue and application thereof | |
CN114933633B (en) | Natural peptide probe for specifically recognizing FGFR4 and application thereof | |
CN111675750B (en) | Tumor targeting peptide aiming at carcinoembryonic antigen related adhesion molecule CEACAM and application thereof | |
CN103911017B (en) | Cyanine dye compound and preparation method thereof, for dual-use function agent of photodynamic therapy and preparation method thereof | |
CN113880917B (en) | Tumor high affinity peptides and application thereof | |
WO2007088129A2 (en) | Cyanine dye compounds linked to metal chelator for bi-modal diagnostic imaging | |
CN112043839A (en) | Radioisotope-labeled polypeptide imaging agent targeting transferrin receptor and application thereof | |
CN114573558B (en) | Water-soluble methyl benzyl ether derivative, positron nuclide probe, nuclide marker, preparation method and application | |
CN116063379A (en) | EphA2 targeting polypeptides and uses thereof | |
CN113817023B (en) | FGFR 4-targeted affinity peptide and application thereof | |
CN115286693A (en) | Tumor targeting peptide aiming at carcinoembryonic antigen related cell adhesion molecule CEACAM6 and application thereof | |
CN112480212A (en) | High-affinity peptide of targeted hepatocyte growth factor and application thereof | |
CN114177314B (en) | Application of thymic pentapeptide and its derivative in preparing tumor diagnosis and/or treatment reagent | |
CN113813405A (en) | Molecular imaging probe based on lisinopril and application thereof | |
CN114288426B (en) | Application of eribante and derivatives thereof in preparation of tumor diagnosis and/or treatment reagent | |
CN115317627B (en) | Application of ABT-510 peptide in preparation of tumor imaging agent | |
CN116813704B (en) | Tumor targeting fluorescent molecular probe and application thereof | |
CN115819525A (en) | Tumor-targeted typhus toxin B subunit mimic peptide and application thereof | |
CN116023432A (en) | Bissialoganglioside GD2 affinity peptide and application thereof | |
CN117946209A (en) | Tumor targeting molecular probe and preparation method and application thereof | |
CN117924419A (en) | Affinity peptide of targeted EGF receptor 2 and application thereof | |
Chapeau et al. | eTFC-01: a dual-labeled chelate-bridged tracer for SSTR2-positive tumors | |
TW202327665A (en) | New peptide-based diagnostic and therapeutic agents | |
CA3205920A1 (en) | A tracer compound and a preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220920 |